This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Company News for Sep1, 2020
by Zacks Equity Research
Companies In The News Are: CTLT, TSLA, AIMT, AMZN.
Catalent (CTLT) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Catalent (CTLT) delivered earnings and revenue surprises of 7.14% and 0.46%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Catalent (CTLT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Catalent (CTLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Editas' (EDIT) Earnings Beat in Q2, Revenues Improve Y/Y
by Zacks Equity Research
Editas' (EDIT) both bottom and the top line better estimates for the second quarter of 2020.
Moderna (MRNA) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investors focus is likely to be on the progress of its pipeline candidates, especially coronavirus vaccine candidate, on the second-quarter earrings call.
Moderna Collaborates to Support Coronavirus Vaccine Supply
by Zacks Equity Research
Moderna (MRNA) signs manufacturing deal with Europe-based pharma company, Rovi, to support supply of its coronavirus vaccine in ex-US markets.
Moderna Completes Enrollment in Phase II Coronavirus Study
by Zacks Equity Research
Moderna (MRNA) is progressing well with its coronavirus vaccine development. It completes enrollment in a phase II study and finalizes phase III study protocol.
Moderna Collaborates With Catalent for Coronavirus Vaccine
by Zacks Equity Research
Moderna (MRNA) teams up with Catalent for large-scale, commercial fill-finish manufacturing of the former's mRNA-based COVID-19 vaccine candidate.
3 Stocks to Buy as Companies Speed Up Vaccine Production
by Ritujay Ghosh
Although the FDA is yet to approve a drug or treatment for COVID-19, companies have already started ramping up manufacturing lines to meet global demand if any of the experimental vaccines succeed.
Should You Invest in the SPDR SP Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
Catalent (CTLT) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Catalent (CTLT) delivered earnings and revenue surprises of 2.04% and 10.18%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
PCRX or CTLT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PCRX vs. CTLT: Which Stock Is the Better Value Option?
Catalent (CTLT) Reports Next Week: What to Expect
by Zacks Equity Research
Catalent (CTLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Catalent (CTLT) Matches Q2 Earnings Estimates
by Zacks Equity Research
Catalent (CTLT) delivered earnings and revenue surprises of 0.00% and 3.46%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Catalent (CTLT) Reports Next Week: What You Should Expect
by Zacks Equity Research
Catalent (CTLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Catalent (CTLT) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Catalent (CTLT) delivered earnings and revenue surprises of 8.33% and 4.45%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stocks Nov 5 Earnings Roster: AGN, REGN & More
by Zacks Equity Research
Let us take a look at five drug/biotech companies, which are supposed to release their quarterly results on Nov 5.
Earnings Preview: Catalent (CTLT) Q1 Earnings Expected to Decline
by Zacks Equity Research
Catalent (CTLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CTLT vs. NBIX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
CTLT vs. NBIX: Which Stock Is the Better Value Option?
Aurinia Pharmaceuticals (AUPH) Catches Eye: Stock Jumps 6.2%
by Zacks Equity Research
Aurinia Pharmaceuticals (AUPH) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
CTLT or NBIX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CTLT vs. NBIX: Which Stock Is the Better Value Option?
JAZZ vs. CTLT: Which Stock Is the Better Value Option?
by Zacks Equity Research
JAZZ vs. CTLT: Which Stock Is the Better Value Option?
Lannett (LCI) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Lannett (LCI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Catalent (CTLT) Upgraded to Buy: Here's Why
by Zacks Equity Research
Catalent (CTLT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Catalent (CTLT) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Catalent (CTLT) delivered earnings and revenue surprises of 9.38% and 0.37%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?